tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mark Breidenbach, 127 are a BUY (97.69%), 3 are a HOLD (2.31%).
Analyst Mark Breidenbach, carries an average stock price target met ratio of 32.57% that have a potential upside of 40.95% achieved within 154 days.
Mark Breidenbach’s has documented 242 price targets and ratings displayed on 22 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on NRIX, Nurix Therapeutics at 04-Sep-2024.
Analyst best performing recommendations are on KDMN (KADMON HOLDINGS).
The best stock recommendation documented was for ARVN (ARVINAS) at 12/14/2020. The price target of $80 was fulfilled within 8 days with a profit of $21.62 (37.03%) receiving and performance score of 46.29.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$10
$8.89 (800.90%)
9 days ago
(14-May-2025)
2/10 (20%)
$9.05 (952.63%)
94
Buy
$9
$7.89 (710.81%)
$10
9 days ago
(14-May-2025)
0/3 (0%)
$8.05 (847.37%)
Buy
$7
$5.89 (530.63%)
$9
9 days ago
(14-May-2025)
2/9 (22.22%)
$6.05 (636.84%)
3
Buy
$8
$6.89 (620.72%)
$9
2 months 4 days ago
(19-Mar-2025)
0/10 (0%)
$6.31 (373.37%)
Buy
$14
$12.89 (1161.26%)
2 months 9 days ago
(14-Mar-2025)
1/3 (33.33%)
$12.06 (621.65%)
192
What Year was the first public recommendation made by Mark Breidenbach?
